Prosetta Biosciences Receives $31,000,000 Series D Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=004f9e6d-fa86-4930-81ae-4c449f3c5c9e - Date
12/4/2015 - Company Name
Prosetta Biosciences - Mailing Address
670 Fifth Street San Francisco, CA 94107 USA - Company Description
Prosetta Biosciences, Inc. is a biotechnology company developing novel small-molecule antiviral therapeutics based on over 25 years of basic research on the Cell-Free Protein Synthesizing Systems (CFPSS) by scientists at the University of California, San Francisco and the University of Washington, Seattle. - Website
http://www.prosetta.com - Transaction Type
Venture Equity - Transaction Amount
$31,000,000 - Transaction Round
Series D - Proceeds Purposes
The net proceeds from the private placement will be used primarily for research and development, with an emphasis in the fields of central nervous system diseases and disorders, oncology, inflammation, antiinfectives, vaccines, animal health and biodefense, among other fields, and for working capital and general corporate purposes. - M&A Terms
- Venture Investor
Fred Alger Management - Venture Investor
Takeda Ventures
